In the end, if we can increase access to these tools while maintaining oversight, and put patient outcomes over profits, that is what will ultimately move the needle on the proverbial scale in the pandemic of excess weight. And Cheng noted that: It is better to use FDA approved treatments rather than experimental and unproven treatments. Moreover, it is important to speak with your healthcare professional regarding the use of GLP-1 or microdosing, he emphasized
We also conducted an as treated analysis assessing only active treatment from first initiation until first break of treatment, where cohort members were followed from index date until first registration of suicide or suicide attempts, emigration, death, switching to the other study drug or reaching the end of their first treatment period
Explore Diabetes and Endocrinology Services at NewYork-Presbyterian While GLP-1s are an effective form of treatment for people who medically require them, microdosing them is not an officially recognized standard of care, says Dr
A healthcare professional should evaluate persistent or significant symptoms
Data availability The datasets used and/or analyzed during this study consist of aggregate data sourced from the TriNetx platform
If you have obesity and heart disease or sleep apnea, Medicaid likely covers a GLP-1 in your state even if it doesnt cover obesity treatment generally